Departamento de Saúde Coletiva, Universidade Estadual de Campinas - Campinas (SP), Brasil.
Prefeitura de Campinas - Campinas (SP), Brasil.
Rev Bras Epidemiol. 2021 Jan 6;24:e210008. doi: 10.1590/1980-549720210008. eCollection 2021.
To estimate the prevalence of use of oral medications for the treatment of diabetes, as well as the distribution of sources for obtaining according to sociodemographic variables, in the Brazilian states' capitals and in the Federal District, and their evolution from 2012 to 2018.
Cross-sectional and population-based study with individuals aged ≥ 20 years who reported a medical diagnosis of diabetes, interviewed through Vigitel from 2012 to 2018. We estimated the prevalence of use and the distribution of sources for obtaining according to sociodemographic variables (95%CI). We checked differences among proportions using the Pearson's χ2 test (Rao-Scott), with a significance level of 5%.
There was an increase in the prevalence of use of oral medications for the treatment of diabetes from 77.4 to 85.2% between 2012 and 2018, and a decrease in obtaining in the Health Unit Pharmacies of the Unified Health System (SUS), while there was an increase in obtaining in Popular Pharmacies.
In Brazil, SUS remained the main source for obtaining oral antidiabetic drugs, financing more than 70% of them in the country, considering the Health Unit Pharmacies and Popular Pharmacies, thereby showing the importance of public Pharmaceutical Policies in guaranteeing the access to medications by the Brazilian population, as well as in reducing inequities in the country. Nevertheless, the migration of obtaining by users from SUS Health Units to Popular Pharmacies suggests the weakening the responsibility of Primary Health Care in the provision oral antidiabetic drugs, thereby undermining the bond and the longitudinal care.
估计巴西各州首府和联邦区用于治疗糖尿病的口服药物的使用情况，以及根据社会人口学变量获得药物的来源分布情况，并评估 2012 年至 2018 年期间的变化情况。
这是一项基于人群的横断面研究，纳入 2012 年至 2018 年期间通过 Vigitel 调查、报告患有糖尿病的年龄≥20 岁的个体。我们根据社会人口学变量（95%CI），估计使用情况和获得来源的分布情况。我们使用 Pearson χ2 检验（Rao-Scott）比较比例之间的差异，显著性水平为 5%。
2012 年至 2018 年间，治疗糖尿病的口服药物使用率从 77.4%增加到 85.2%，而从统一卫生系统（SUS）的卫生单位药房获得药物的比例下降，而从大众药房获得药物的比例上升。
在巴西，SUS 仍然是获得口服抗糖尿病药物的主要来源，考虑到卫生单位药房和大众药房，SUS 为全国超过 70%的药物提供资金，这表明公共药品政策在保障巴西民众获得药物方面的重要性，以及在减少国家内部的不平等方面的重要性。然而，用户从 SUS 卫生单位到大众药房获得药物的迁移表明，初级卫生保健在提供口服抗糖尿病药物方面的责任正在减弱，从而破坏了联系和纵向护理。
